NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 ...(ticals is a US-based biotechnology compa...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
Date:9/26/2007
ticals is a US-based biotechnology company focused on drug development for Neurofibromatosis Types 1 and 2 and related sporadic tumors. Neurofibromatosis, or NF, is a genetic disorder characterized by the development of tumors along nerves. NexGenix has assembled a team of top NF clinicians and researchers on its Scientific Advisory Board and has developed a proprietary screening platform for both Neurofibromatosis Type 1 and 2. NexGenix will soon seek an IND for a unique treatment for NF1.
For more information, please visit the NexGenix website at http://www.nexgenixpharm.com. The information on our website does not, however, form a part of this press release.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements.
'/>"/>
| SOURCE NexGenix Pharmaceuticals Holdings, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche
Post Your Comments:
Breaking Biology Technology:China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
[0] China Biologic Products to Ring NASDAQ Opening Bell[0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head[0] Martek Signs Sole-Source Supply Agreement with Fonterra[0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Other Biology Technology:deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results 2New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 2New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 3New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 4Peptimmune Presentations at Upcoming Events 2
Breaking Biology News(10 mins):Climate projections underestimate CO2 impact 2Canna can: Ornamental eliminates pollutants from stormwater runoff 2Takeda Receives FDA Complete Response Letter for the Investigational Fixed Dose Combination of alogliptin and ACTOS 28R 29 28pioglitazone HCl 29 for 4944 1Takeda Receives FDA Complete Response Letter for the Investigational Fixed Dose Combination of alogliptin and ACTOS 28R 29 28pioglitazone HCl 29 for 4944 2Takeda Receives FDA Complete Response Letter for the Investigational Fixed Dose Combination of alogliptin and ACTOS 28R 29 28pioglitazone HCl 29 for 4944 3Time to tap climate change combating potential of the worlds ecosystems 9790 1Time to tap climate change combating potential of the worlds ecosystems 9790 2Time to tap climate change combating potential of the worlds ecosystems 9790 3Time to tap climate change combating potential of the worlds ecosystems 9790 4Time to tap climate change combating potential of the worlds ecosystems 9790 5Center for Technology and Aging Releases Guidelines for 24500 000 Medication Optimization Diffusion Grants Program 56238 1Center for Technology and Aging Releases Guidelines for 24500 000 Medication Optimization Diffusion Grants Program 56238 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |